Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 2/20 | 0.32 |
| ▸ | MC5R | P33032 | 2/20 | 0.32 |
| ▸ | MC3R | P41968 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507093 | 1.00 | REN (0.46) | RENKCNH2TDP1KDM1AMC4R | |
| SCHEMBL4503660 | 0.92 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL4503664 | 0.92 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL4514582 | 0.87 | REN (0.41) | RENKCNH2CYP3A4 | |
| SCHEMBL4498916 | 0.87 | REN (0.41) | RENKCNH2CYP3A4 | |
| SCHEMBL4504320 | 0.80 | REN (0.35) | RENKCNH2CYP3A4 | |
| SCHEMBL4504318 | 0.80 | REN (0.35) | RENKCNH2CYP3A4 | |
| SCHEMBL4598793 | 0.79 | REN (0.33) | REN | |
| SCHEMBL4491475 | 0.78 | REN (0.55) | REN | |
| SCHEMBL1913258 | 0.78 | REN (0.55) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885KCNH2 403/4885TDP1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.